Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-vascular endothelial growth factor transgenic mice

Histology and Histopathology

Volumn 26, Issue 3, 2011, Pages 285-296

  Canavese, Miriam ^a   Altruda, F ^a   Silengo, L ^a   Castiglioni, V ^b,c   Scanziani, E ^b,c   Radaelli, E ^b,c  

^a UNIVERSITY OF TURIN   (Italy)

^b Filarete Foundation   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Disease animal models; Psoriasis; Skin; VEGF

Indexed keywords

CHEMOKINE; CYTOKERATIN 14; CYTOKINE; VASCULOTROPIN A;

AGING; ANIMAL; ARTICLE; EXTERNAL EAR; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MALE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PSORIASIS; SKIN; TRANSGENIC MOUSE;

AGING; ANIMALS; CHEMOKINES; CYTOKINES; EAR, EXTERNAL; FEMALE; IMMUNOHISTOCHEMISTRY; KERATIN-14; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PSORIASIS; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MUS MUSCULUS;

EID: 79952338652     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Arican O., Aral M., Sasmaz S. and Ciragil P. (2005). Serum levels of TNF-α, IFN-α, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 5, 273-279. (Pubitemid 41577417)
2. Bettelli E., Korn T., Oukka M. and Kuchroo V.K. (2008). Induction and effector functions of Th17 cells. Nature 453, 1051-1057. (Pubitemid 351871737)
3. Bhushan M., McLaughlin B., Weiss J.B. and Griffiths C.E. (1999). Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br. J. Dermatol. 141, 105410-60.
4. Blauvelt A. (2007). New concepts in the pathogenesis and treatments of psoriasis: key roles for IL-23, IL-17A and TGF-ß1. Expert Rev. Dermatol. 2, 69-78.
5. Borska L., Andrys C., Krejsek J., Hamakova K., Kremlacek J., Ettler K. and Fiala Z. (2008). Serum levels of pro-inflammatory cytokine interleukin-12 and anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen. Int. J. Dermatol. 47, 800-805.
6. Creamer D., Sullivan D., Bicknell R. and Barker J. (2002). Angiogenesis in psoriasis. Angiogenesis 5, 23123-6.
7. Danilenko D.M. (2008). Preclinical Models of Psoriasis. Vet. Pathol. 45, 563-575.
8. Deeva I., Mariani S., De Luca C., Pacifico V., Leoni L., Raskovic D., Kharaeva Z., Korkina L. and Pastore S. (2010). Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokines 49, 163-170.
9. Detmar M., Brown L.F., Schön M.P., Elicker B.M., Velasco P., Richard L., Fukumura D., Monsky W., Claffey K.P. and Jain R.K. (1998). Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111, 1-6. (Pubitemid 28309201)
10. Duan H., Koga T., Kohda F., Hara H., Urabe K. and Furue M. (2001). Interleukin-8-positive neutrophils in psoriasis. J. Dermatol. Sci. 26, 119-124. (Pubitemid 32510719)
11. Elias P.M., Arbiser J., Brown B.E., Rossiter H., Man M.Q., Cerimele F., Crumrine D., Gunathilake R., Choi E.H., Uchida Y., Tschachler E. and Feingold K.R. (2008). Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis and the development of epidermal hyperplasia. Implications for pathogenesis of psoriasis. Am. J. Pathol. 173, 689-699.
12. Ghoreschi K., Weigert C. and Röcken M. (2007). Immunopathogenesis and role of T cells in psoriasis. Clin. Dermatol. 25, 574-580. (Pubitemid 350087604)
13. Gillitzer R. and Goebeler M. (2001). Chemokines in cutaneous wound healing. J. Leukoc. Biol. 69, 513-21. (Pubitemid 32294835)
14. Gudjonsson J.E., Johnston A., Sigmundsdottir H. and Valdimarsson H. (2004). Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 135, 1-18.
15. Harvima I.T., Nilsson G., Suttle M.M. and Naukkarien A. (2008). Is there a role for mast cells in psoriasis? Arch. Dermatol. Res. 300, 471-478.
16. Heidenreich R., Röcken M. and Ghoreschi K. (2008). Angiogenesis: the new potential target of the therapy of psoriasis? Drugs New Perspect 21, 97-105. (Pubitemid 351628234)
17. Heidenreich R., Röcken M. and Ghoreshi K. (2009). Angiogenesis drives psoriasis pathogenesis. Int. J. Exp. Pathol. 90, 232-248.
18. Hvid H., Teige I., Kvist P.H., Svensson L. and Kemp K. (2008). TPA induction leads to a Th17-like response in K14-VEGF transgenic mice: a novel in vivo screening model of psoriasis. Int. Immunol. 20, 1097-1106.
19. Johansen C., Funding A.T., Otkjaer K., Kragballe K., Jensen U.B., Madsen M., Binderup L., Skak-Nielsen T., Fjordin M.S. and Iversen L. (2006). Protein expression of TNF-α in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J. Immunol. 176, 1431-1438. (Pubitemid 43134285)
20. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., Everitt D.E., Frederick B., Zhu Y., Graham M.A., Pendley C.E. and Mascelli M.A. (2004). A phase I study evaluating the safety, pharmacokinetics and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123, 1037-1044. (Pubitemid 39586823)
21. Krueger J.G. and Bowcock A.M. (2005). Psoriasis pathophysiology: current concepts of pathogenesis. Ann. Rheum. Dis. 64, ii30-ii36. (Pubitemid 40288517)
22. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Kamian F., Dhodapkar M. and Krueger J.G. (2004). Increased expression of interleukin 23 p19 and 40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125-30. (Pubitemid 38076484)
23. Loffredo S., Ayala F., Marone G., Delfino G., Stranges S. and Marone G. (2009). Immunopathogenesis of psoriasis and pharmacological perspectives. J. Rheumatol. (Suppl. 83), 9-11.
24. Louden B.A., Pearce D.J., Lang W. and Feldman S.R. (2004). A simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol. Online J. 10,7.
25. Lowes M.A., Bowcock A.M. and Krueger J.G. (2007). Pathogenesis and therapy of psoriasis. Nature 445, 866-73.
26. Man X.Y., Yang X.H., Cai S.Q., Yao Y.G. and Zheng M. (2006). Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) in human epidermis. Mol. Med. 12, 127-136. (Pubitemid 44646341)
27. Nestle F.O., Kaplan D.H. and Barker J. (2009). Psoriasis. N. Engl. J. Med. 361, 496-509.
28. Nickoloff B.J. (2007). Cracking the cytokine code in psoriasis. Nat. Med. 13, 242-244. (Pubitemid 46376653)
29. Nickoloff B.J. and Nestle F.O. (2004). Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113, 1664-1675. (Pubitemid 39071656)
30. Numasaki M., Fukushi J., Ono M., Narula S.K., Zavodny P.J., Kudo T., Robbins P.D., Tahara H. and Lotze M.T. (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620-2627. (Pubitemid 36857622)
31. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q. and Dong C. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141. (Pubitemid 41541791)
32. Pauls K., Schön M., Kubitza R.C., Homey B., Wiesenborn A., Lehmann P., Ruzicka T., Parker C.M. and Schön M.P. (2001). Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J. Invest. Dermatol. 117, 569-575. (Pubitemid 32955582)
33. Radaelli E., Del Piero F., Aresu L., Sciarrone F., Vicari N., Mattiello S., Tagliabue S., Fabbi M. and Scanziani E. (2009). Expression of major histocompatibility complex class II antigens in porcine leptospiral nephritis. Vet. Pathol. 46, 800-809.
34. Schön M.P. (1999). Animal models of psoriasis- what we can learn from them? J. Invest. Dermatol. 112, 405-410. (Pubitemid 29171927)
35. Shehata I.H. and Elghandour T.M. (2007). A possible pathogenic role of CD4+CD25+ T-regulatory cells in psoriasis. Egypt J. Immunol. 14, 21-31.
36. Teige I., Hvid H., Svensson L., Kvist P.H. and Kemp K. (2009). Regulatory T cells control VEGF-dependent skin inflammation. J. Invest. Dermatol. 129, 1437-45.
37. Theoharides T.C., Zang B., Kempuraj D., Tagen M., Vasiadi M., Angelidou A., Alysandratos K.D., Kalogeromitros D., Asadi S., Stavrianeas S., Peterson E., Leeman S. and Conti P. (2010). IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA 107, 4448-53.
38. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D. and McDonald D.M. (1999). Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511-2514.
39. Xia Y.P., Li B., Hylton D., Detmar M., Yancopoulos G.D. and Rudge J.S. (2003). Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102, 161-168. (Pubitemid 36759650)
40. Yalçin B., Tezel G.G., Arda N., Erman M. and Alli N. (2007). Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis. Anal. Quant. Cytol. Histol. 29, 358-364. (Pubitemid 350304993)
41. Zhang Y., Furumura M. and Morita E. (2008). Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165. Growth Factors 26, 125-131. (Pubitemid 351911394)
42. Zhang Y., Matsuo H. and Morita E. (2005). Vascular Endothelial growth factor 121 is the predominant isoform in the psoriatic scales. Exp. Dermatol. 14, 758-764. (Pubitemid 41419463)
43. Zollner T.M., Asadullah K. and Schön M.P. (2007). Targeting leukocyte trafficking to inflamed skin- still an attractive therapeutic approach? Exp. Dermatol. 16, 1-12. (Pubitemid 44890345)